- KR₩188bn
- KR₩210bn
- KR₩138bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.49 | ||
| Price to Tang. Book | 2.93 | ||
| Price to Free Cashflow | 29.72 | ||
| Price to Sales | 1.36 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -15.28% | ||
| Return on Equity | -18.41% | ||
| Operating Margin | -10.15% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 136,123.66 | 130,031.78 | 140,317.99 | 165,205.51 | 137,878.04 | n/a | n/a | -0.08% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CTCBIO Inc. is a Korea-based company engaged in the manufacture and marketing of pharmaceuticals, veterinary drugs, animal feed supplements and functional foods. It pharmaceuticals include anticancer agents, antibiotics, bone injury treatments, antiulcer agents, blood flow stimulants and others. Its veterinary drugs include vaccines, antibiotics, immune enhancers, enzymes, organic acid, avian influenza-related agents and others. Its animal feed supplements include pigments, kapok seed meal, sesame meal and others. Its functional food business includes the development and manufacture of enzymes, lactobacillus and related products mainly used in dairy products. It also involves in the development of pharmaceutical manufacturing technology and know-how. The Company distributes its products within domestic market and to overseas markets.
Directors
- Hong Yeol Jeon CCE (56)
- Min Gu Lee CCE (60)
- Jeong Hyo Lee MDR (53)
- Sang Ho Bae OTH (69)
- Dae Geon Choi OTH (54)
- Jun Seok Byun IND (49)
- Geum Ho Lee IND (48)
- Jeong Hui Han NID (51)
- Cheol Min Kim NID (48)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- December 28th, 1995
- Public Since
- February 21st, 2002
- No. of Shareholders
- 9,196
- No. of Employees
- 258
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Korea Exchange - KOSDAQ- Shares in Issue
- 23,908,775
- Address
- 6F, 296, Jungdae-ro, Songpa-gu, HWASEONG, 18469
- Web
- http://www.ctcbio.com/
- Phone
- +82 216618800
- Auditors
- Samil Accounting Corp.
Upcoming Events for 060590
Similar to 060590
AbClon
Korea Exchange - KOSDAQ
ADBiotech Co
Korea Exchange - KOSDAQ
Ahn-Gook Pharmaceutical Co
Korea Exchange - KOSDAQ
Alteogen
Korea Exchange - KOSDAQ
Aminologics Co
Korea Exchange - KOSDAQ
FAQ
As of Today at 19:06 UTC, shares in CTC Bio are trading at KR₩7,870. This share price information is delayed by 15 minutes.
Shares in CTC Bio last closed at KR₩7,870 and the price had moved by -23.59% over the past 365 days. In terms of relative price strength the CTC Bio share price has underperformed the FTSE Developed Asia Pacific Index by -20.25% over the past year.
There is no consensus recommendation for this security.
CTC Bio does not currently pay a dividend.
CTC Bio does not currently pay a dividend.
CTC Bio does not currently pay a dividend.
To buy shares in CTC Bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩7,870, shares in CTC Bio had a market capitalisation of KR₩188bn.
Here are the trading details for CTC Bio:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 060590
Based on an overall assessment of its quality, value and momentum CTC Bio is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CTC Bio. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -25.92%.
As of the last closing price of KR₩7,870, shares in CTC Bio were trading -20.28% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The CTC Bio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩7,870.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
CTC Bio's management team is headed by:
- Hong Yeol Jeon - CCE
- Min Gu Lee - CCE
- Jeong Hyo Lee - MDR
- Sang Ho Bae - OTH
- Dae Geon Choi - OTH
- Jun Seok Byun - IND
- Geum Ho Lee - IND
- Jeong Hui Han - NID
- Cheol Min Kim - NID